EGFR and neoplasm: Consequently, a patient with both EGFR sensitizing mutations and Ras mutations in the tumor may not respond to targeted therapy due to proliferative signal transduction by an active Ras oncoprotein regardless of upstream inhibition of EGFR by a drug.